Roche and Upsher-Smith announce license agreement to develop novel VAP-1 inhibitor
- Details
- Category: Roche
Roche (SIX: RO, ROG: OTCQX: RHHBY) and Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd., announced a worldwide agreement for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases.
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M
- Details
- Category: Bristol-Myers Squibb
To mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.
Roche receives EU approval of Cotellic for use in combination with Zelboraf in advanced melanoma
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved CotellicTM (cobimetinib) for use in combination with Zelboraf® (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease, an area of medicine outside AstraZeneca's strategic focus.
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
- Details
- Category: Bayer
Bayer has submitted an application for marketing authorization in both the European Union and in the United States for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) which is directly placed in the uterus for contraception for up to five years. Long-acting contraception is one of the most effective methods of birth control.
Merck and Pfizer receive FDA Breakthrough Therapy designation for avelumab in metastatic Merkel cell carcinoma
- Details
- Category: Merck Group
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.
More Pharma News ...
- Roche to restructure its manufacturing network for small molecules
- Global partners announce donation of 500 millionth dose of azithromycin
- International study prompts rethink on the rise of diabetes in cities
- Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years
- Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
- Pfizer expands its patient assistance program
- Merck recognized for digital workplace platform